Comparison of Differential Expression of P2Y12 Receptor in Culprit Coronary Plaques in Patients With Acute Myocardial Infarction Versus Stable Angina Pectoris
- Author(s)
- Seong-Wook Park; Seung-Jung Park; Cheol Whan Lee; Ilseon Hwang; Chan-Sik Park; Hyangsin Lee; Duk-Woo Park; Su-Jin Kang; Seung-Whan Lee; Young-Hak Kim
- Keimyung Author(s)
- Hwang, Il Seon
- Department
- Dept. of Pathology (병리학)
- Journal Title
- American Journal of Cardiology
- Issued Date
- 2011
- Volume
- 108
- Issue
- 6
- Abstract
- P2Y12 receptor antagonists may have pleiotropic benefits. Little is known, however, about the
expression of P2Y12 receptors in coronary atherosclerotic plaques. We investigated the expression
of P2Y12 receptor in coronary atherectomy tissues retrieved from patients with acute
myocardial infarction (AMI) or stable angina pectoris (SAP). Tissue specimens were collected
from 35 patients with AMI and 19 with SAP who underwent directional coronary atherectomy.
Specimens were analyzed immunohistochemically using antibodies specific to P2Y12 receptor
and to markers of endothelial cells, macrophages, and smooth muscle cells. The 2 groups had
similar baseline clinical characteristics. Plaque types were more likely to be cellular in the AMI
group. The proportion of areas immunopositive for -smooth muscle actin was smaller but
those positive for CD31 and CD68 were larger in the AMI than in the SAP group. In addition,
the relative area immunopositive for P2Y12 receptor was significantly larger for AMI than SAP
(1.1 0.9% vs 0.5 0.4%, respectively, p <0.001). P2Y12 receptor positivity coincided with
areas positive for CD31 and -smooth muscle actin. In conclusion, P2Y12 receptor is present in
coronary atherosclerotic plaques and is increased in culprit plaques of patients with AMI.
P2Y12 receptor may play a role in plaque destabilization. © 2011 Elsevier Inc. All rights
reserved. (Am J Cardiol 2011;108:799–803)
- Authorize & License
-
- Authorize공개
- EmbargoForever
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.